



Influenza Update

December 17th, 2014

Amy V. Groom, MPH

IHS Immunization Program Manager



Objectives

- Describe current influenza-like-illness trends across the U.S.
- Provide update on current vaccine issues
- Describe current influenza-like-illness trends across the IHS
- Know influenza vaccine coverage rates for your IHS Area

U.S. Influenza Activity


- ILI activity increasing – above national baseline
- Predominantly H3N2
 - Very little H1N1
 - Majority of circulating H3N2 strains are drifted from the H3N2 component in the vaccine
 - If H3N2 continues to predominate, could be severe season
- Currently vaccination coverage - 40.3%
 - General U.S. population 6 months and older, Nov. 2014

FLUVIEW



**A Weekly Influenza Surveillance Report Prepared by the Influenza Division
Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists***

Week Ending November 08, 2014- Week 45




***This map indicates geographic spread and does not measure the severity of influenza activity.**

FLUVIEW



**A Weekly Influenza Surveillance Report Prepared by the Influenza Division
Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists***

Week Ending December 06, 2014- Week 49



*This map indicates geographic spread and does not measure the severity of influenza activity.

Vaccine Issues

- LAIV effectiveness against H1N1
- Drifted H3N2 strain
 - Different from the H3N2 vaccine virus component
 - Vaccine may not work as well against these different viruses
 - For more information:
<http://emergency.cdc.gov/han/han00374.asp>
 - **HOWEVER**
 - Good protection against other H3N2 and influenza B strains
 - May reduce severity of disease caused by drifted H3N2 strain
 - Vaccination remains the most effective tool to prevent influenza

Antiviral Treatment

- Use of neuraminidase inhibitor antiviral medications when indicated for treatment and prevention of influenza is an important adjunct to vaccination.
- Decisions about starting antiviral treatment should not wait for laboratory confirmation of influenza.
- The IHS National Supply Service Center reports
 - Influenza vaccine
 - Abundant supply of Tamiflu® 75 mg caps and Relenza® antiviral treatment regimens
 - Can acquire other Tamiflu preparations as needed.
- Antiviral treatment recommendations:
<http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>


IHS INFLUENZA AWARENESS SYSTEM (IIAS)

All IHS Areas


Influenza-Like Illness (ILI) All Surveillance Years - Continuous

Percentage of Visits for ILI per week


01/04/09 to 12/06/14 (Week 49)



Proportion of Outpatient Visits for Influenza-Like Illness (ILI)
Percent ILI for FluYear 2014 - 2015
ILINet vs. IIAS




All IHS Areas
Influenza-Like Illness (ILI) for All Surveillance Years
Percentage of Visits for ILI per week



Percentage of ILI visits is number of ILI visits divided by total number of daily visits.
 The horizontal line represents the 2013-2014 baseline. The baseline is the mean percentage of patient visits for ILI during non-influenza weeks for the previous three seasons plus two standard deviations.

ILI Activity by IHS Area Week 49



All IHS Areas

Seasonal Influenza Vaccine Coverage by Age Group*

06/29/14 to 12/6/14

Active Clinical Population**

Age Group	Active Clinical Population **	Seasonal Flu Vaccine (At Least 1 Dose) ***	% Seasonal Flu (At Least 1 Dose)	Seasonal Flu Vaccine (At Least 2 Doses)	% Seasonal Flu (At Least 2 Doses)	Total #Doses Administered ****
0 - 5 months	5,423	71	1.3	4	0.1	75
6 - 23 months	27,059	10,684	39.5	1,282	4.7	11,994
2 - 4 years	65,752	16,343	24.9	224	0.3	16,627
5 - 17 years	245,210	69,549	28.4	546	0.2	70,349
18 - 49 years	519,099	112,945	21.8	1,017	0.2	114,388
50 - 64 years	208,078	75,175	36.1	690	0.3	76,164
65 + years	115,913	50,873	43.9	536	0.5	51,723
Children (6 months-17 years)	338,021	96,576	28.6	2,052	0.6	98,970
Adults (18 + years)	843,090	238,993	28.3	2,243	0.3	242,275
All (6 months +)	1,181,111	335,569	28.4	4,295	0.4	341,245

* Limited to sites that exported both doses administered and active clinical population data.

** Active Clinical is defined as patients who have had at least 2 visits in the last 3 years.

*** Number of unique patients with at least 1 dose.


**** Total # Doses Administered = All doses administered to patients including doses not included in coverage calculation due to lack of Active Clinical Population data.

All IHS Areas


Cumulative One-Dose Seasonal Influenza Vaccine Coverage

06/29/14 to 12/06/14

Active Clinical Population



Seasonal Influenza Vaccine Coverage 6 Months and older Active Clinical User



Summary

- ILI activity increasing in the U.S., expected to increase in IHS in coming weeks
- While vaccine effectiveness may be reduced against drifted H3N2 strains, vaccine remains the most effective tool to prevent influenza
 - Currently only 28% of IHS patient population has been vaccinated
- Early antiviral treatment is an important adjunct to vaccination